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Abstract 
Various schemes of prevention measures in public health are developed and 
analyzed on the basis of a general mathematical model. Features related to cost 
issues, including primary and secondary prevention interventions, differential 
survival experiences and communicable diseases are in turn used to show the 
potentialities of the theoretical framework. A numerical application is presented 
with reference to Italian cancer data.   
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1. Introduction and Motivations 
 
Health is widely acknowledged as an economic good representing a pre-requisite for 
individual well-being and economic productivity. Public policy actions focussed on its 
promotion and improvement are an essential factor to sustainable economic welfare and 
prevention measures are often the keys to successful health policies. Socio-economic studies 
provide wide evidence of the positive impact of health promotion on relevant economic 
variables such as labour supply, productivity, wages and earnings (for a review see Suhrke et 
al., 2005); however, unlike direct health services, health promotion programs entail a long-
term distribution of the benefits that makes them less profitable to private firms. It is, 
therefore, the public sector that takes most of the charge of prevention programs and sound 
tools for cost reductions and resource management are becoming more and more crucial in a 
long-term perspective under increasing  public budget constraints. 
A large number of studies in the literature (based on standard statistical modelling or 
developing original mathematical approaches) provide specific, disease-related evaluation 
tools for the impact of prevention measures on various public health and socio-demographic 
aspects of community life (see, among many: Boily et al., 2007, Goldie S. et al., 2006, 
Zethraeus N., 2007). However, in the framework of overall planning, public health policy 
makers often need uniform and comparable tools to evaluate the global impact of prevention 
interventions on budget issues and community life. As clearly explained in Goldie (2003), 
"No clinical trial or single cohort study will be able to simultaneously consider all of these 
components. Cost-effectiveness analysis and disease-simulation modeling, capitalizing on 
data from multiple sources, can serve as a valuable tool to extend the time horizon of clinical 
trials, to evaluate more strategies than possible in a single clinical trial, and to assess the 
relative costs and benefits of alternative policies to reduce mortality". Only few studies 
examine the impact of prevention on public health expenditure in a comprehensive model-
theoretical approach, where the effects of global resource allocation are evaluated (see, for 
instance, Davies R. et al., 2003, Haddix A. et al., 2003, Mackinnon D. and Dwyer J., 1993).  
This paper offers a modelling approach to the general problem of design and evaluation of 
prevention measures under an essentially budget-management perspective. Various design 
aspects of prevention must be taken into account when organizing and scheduling public 
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health interventions, out of which the demographic structure of the reference population and 
the disease epidemiology are the most relevant. Specific issues to be included in a modelling 
approach are the distinction between primary and secondary prevention measures, direct and 
indirect costs of disease treatment, decision strategy indicators. However, while a primary 
prevention analysis only involves a simple community model with individual costs, secondary 
prevention schemes involve variable treatment costs, unit prevention costs and a clear 
epidemiological picture: the disease prevalence in the reference population and a multistate 
distribution of pre-clinical, asymptomatic conditions among affected individuals. 
The scheme used in the following starts in section 2 with a simple primary prevention model 
and expands it to a multistate, secondary prevention evaluation model. Section 3 presents an 
application to overall Italian cancer data. In section 4 extensions of the general model are 
discussed to further include more complex situations, involving disease prevalence instability, 
sorted risk groups and differential survival experiences. Conclusions and materials for further 
developments and applications are presented in section 5. 
 
 
2. General Prevention Models  
 
As remarked in the previous section, primary and secondary prevention measures act at 
different population/disease level and interactions. In this section prevention evaluation 
schemes for primary and secondary interventions will be presented with regard to expenditure 
and savings obtained by a public health system, without selection of admission of the affected 
individuals to treatment (i.e.: all affected individual of the reference population have equal 
access to clinical treatment). A further hypothesis used in the following is that the disease 
prevalence in absence of prevention interventions is stable and constant over the time horizon 
considered; consequences of dropping this hypothesis will be briefly analysed in section 5, 
where possible extensions of the model will be presented. 
A simple scheme of primary interventions may be thought of as an information campaign 
directed to the general population or a sorted proportion of it. It involves a roughly per capita 
expenditure and results into a reduction of the disease incidence and prevalence, at variable 
levels, corresponding to the effectiveness of the campaign.  
4 
 
Let ppP   be the total number of individuals in a population, divided into Pp   
individuals that will eventually become affected by some disease under study ( being the 
known prevalence of the disease in the general population) and Pp )1(   individuals that 
will not develop the disease. A public health system that must treat all affected individuals has 
a predictable, total, disease-related cost C  given by 
 
ApAC  0        (1) 
 
where 0A  is a general fixed system cost and A  is the variable treatment cost per affected 
individual. 
Thus, given a per capita prevention expenditure e and a corresponding proportion  of 
individuals positively responding to the prevention measures, the total cost (1) becomes 
 
  ePpAAC  1ˆ 0       (2) 
 
Note that the term P does not include already affecetd individuals, as they are not the object 
of the prevention actions and are, therefore, included in the fixed cost term 0A . 
Using (1) and (2), a system saving is thus attained if 
 
0ˆ  ePpACCS     Ae      (3) 
 
which provides an exact evaluation of the profitability of a prevention investment: in fact, this 
turns out to be economically profitable only when the variable treatment costs and/or the 
disease prevalence are high enough to compensate for the prevention costs. 
A more complex modelling scheme is to be used to evaluate secondary prevention measures 
as these interventions aim at different results and involve various, disease-related types of 
individuals. In this case the reference population, target of these prevention measures, 
includes those already affected individuals at asymptomatic, pre-clinical stages aiming at an 
early detection of the disease and at its early treatment (Simeonsson, 1991).  
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Let now be the total population given by ppP   with p asymptomatic individuals already 
affected by the disease under study at n increasing levels of severity, and p healthy 
individuals, and let i  ni ,,1  be the known prevalences of each level of severity of the 
disease in the population. 
Similarly to (1), the public health system in absence of prevention measures has a predictable, 
total, disease-related cost C  given by 
 



n
i
ii PAC
1
0         (4) 
 
where 0A  is a general fixed system cost and nii ,,1,   are the variable treatment costs per 
affected individual and related to the n levels of severity of the disease. Note that the 
distribution of individuals in (4) is supposed to be induced by the disease symptomatology: 
i.e., affected individuals enter the cost function (4) at a level corresponding to detectable 
symptoms. 
Possible prevention measures can be thought of as some form of screening over the entire 
population P to detect all affected individuals before their disease becomes symptomatic (i.e., 
at a lower level of severity). Let e be the unit cost of the prevention operations; the total cost 
of prevention is therefore given by 
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and the prevention cost per affected individual actually detected is then given by 
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The effects of prevention on the number of affected individuals are thus given by their 
redistribution among the n levels of severity (with the corresponding changes in the treatment 
costs) according to a lower triangular transition matrix  
njiij ...1; 
 Π  such that: 
 
1
1
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where underlying  hypotheses are: 
 the disease prevalence does not changes within the time horizon considered, 
 prevention measures do not interact with the symptomatology of the disease (i.e.: the 
level of severity detected by prevention measures cannot be higher than the level 
corresponding to detectable symptoms). 
By using (4), the total system cost, when prevention measures are put in place, is thus given 
by 
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where the variable treatment cost of the i-th level of severity is now given by the algebraic 
sum of 
 
 Pii : the cost of individuals detected at symptomatic level of severity; 
 

n
ij
jjii P
1
 : the cost of individuals detected at the i-th level of severity with a 
higher symptomatic level of severity; 
 


1
1
i
j
iiji P : the cost of individuals with i-th symptomatic level of severity 
detected at a lower level of severity; 
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 

n
ij
jji P
1
 : the prevention costs per individual with i-th symptomatic level 
detected at a lower level of severity. 
  
A system saving is thus attained if 
0ˆ  CCS       (8) 
 
which, by using (4) and (7), becomes 
 
0
1
1 12
1
1
1
1 1
  

 



 
n
i
n
ij
jji
n
i
i
j
ijii
n
i
n
ij
jjii       (9) 
 
By using some simple algebra and solving for  we have 
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Thus an economically sound prevention policy can be effectively set up when the cost of one 
asymptomatic detected individual is smaller than the average cost reduction, weighed by the 
newly detected prevalences of each level of severity. In the absence of further, specific 
information on the morbidity of the disease under study at various levels of severity (i.e.: no 
direct or indirect information available on the ij  terms), the assumptions that the whole 
population P undergoes the prevention screening and that no biased error occurs during the 
screening operation, provide a reasonable ground to the conservative hypothesis that the 
prevalence rates i  ni ,,1  of the general population also apply to the various levels of 
severity. This implies that all transitions ij can be approximated by the corresponding 
prevalence rates niijj ,,1,     and, similarly to (3),  (10) can be expressed in terms of 
the unit cost e of prevention operations and becomes 
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Under the hypothesis of non-decreasing costs between the disease stages and the trivial 
remark that 0i  for at least two different i’s, ni 1 , then nie i 1  0    and  0e
if and only if njiiij 1,   j 0  .  
 
 
3. An Application to Italian Cancer Data 
 
The various tumor forms are a typical example falling into most of the modelling hypotheses 
as in section 2; even when limited to any incidence sub-populations, these may, however, be 
easily detected (male-female, for instance). In the following, simple numerical examples of 
prevention schemes are presented, based on the model in the previous section and using 
cancer treatment- and cost-data from heteregeneous, external studies. Prevalence and global 
unit cost data corresponding to various primary tumor sites are shown in table 1. 
 
Table 1. - Unit treatment costs and prevalence by tumor primary site. 
primary prevalence%* unit cost (×1000€)** 
lung 0,17 36 
stomach 0,12 19 
melanoma 0,27 21 
colon/rectum 0,69 24 
cervix 0,05 10 
breast 2,26 17 
prostate 1,23 19 
leukemias 0,09 77 
 
* A.I.R.TUM. – I tumori  in Italia  (2012) - http://www.tumori.net 
** CENSIS, from Economist Intelligent Unit (2010) 
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While no staging data are required in this simplified application of the primary prevention 
scheme as from (3), the secondary prevention scheme requires cost and prevalence 
distribution data for the application of (11). In the next, for the sake of homogeneity of the 
various primary tumor sites and in order to outline the use of the model, the staging 
classifications have been reduced to 3 for each type of tumor on the basis of epidemiological 
and clinical data drawn from the existing medical literature. However, as the detailed cost 
distribution at each stage is not immediately available, various distributional hypotheses were 
applied to the data in table 1 and the resulting expenditure limits were computed according to 
(11). 
Figures 1, A and B, show two examples of primary prevention schemes where: A) the 
expenditure limits are mapped against the corresponding total prevalences, and B) the 
expenditure limits are mapped against the total unit treatment costs. 
Figures 2 and 3, A and B, show two examples of secondary prevention schemes with different 
distributional hypotheses among the stages, where, as above: A) the expenditure limits are 
mapped against the corresponding total prevalences, and B) the expenditure limits are mapped 
against the total unit treatment costs. 
 
 
FIGURES 1 – Tumor types by primary prevention expenditure limit and A) prevalence B) unit 
treatment cost. 
A       B 
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FIGURES 2 – Tumor types by secondary prevention expenditure limit and A) prevalence B) unit 
treatment cost, with a stage cost distribution: 2312 10;2    
A       B 
  
 
 
FIGURES 3 – Tumor types by secondary prevention expenditure limit and A) prevalence B) unit 
treatment cost, with a stage cost distribution: 2312 5.1;5    
A       B 
 
 
 
A visual inspection of figures 1, 2 and 3 shows that, both in the primary and the secondary 
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pathology prevalence while no direct dependency can be detected between prevention 
expenditure limit and the unit treatment. 
The results of these simple numerical applications highlight the role of the disease prevalence 
in the definition of the prevention expenditure limit. In fact, while the unit cost enters (11) 
only as a cost redistribution among the stages and, therefore, as a relative (not absolute) 
budget savings, the disease prevalence is what actually provides a larger probability to detect 
an affected individual and of not wasting prevention resources in the search of an unlikely 
event. 
 
 
4. Extending the Model 
 
By defining the vectors  
nii ,,1  β  and   nii ,,1 α  and the Hollow matrices 
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where nI  is the nn  identity matrix, (11) can be re-written as  
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where n1  is the n-vector with elements all equal to 1’s. Note also that 2B  is skew-symmetric 
and both 
1B  and 2B  are known as generalized Conference matrices. 
From (12) direct, a geometric interpretation of the upper limit to prevention unit expenditures 
can be drawn in terms of prevalences and treatment costs. In fact, vectors α , β  and n1  
represent, respectively, the treatment cost profile of the disease under study, the prevalence 
profile and the profile of an unscreened individual; therefore the degenerate, bilinear forms in 
(12) map, respectively, a prevalence profile and an unscreened individual onto the cost space, 
the degenerate condition accounting for (6). 
This vector setting of the prevention expenditure limit (12) may be effectively used, by direct 
modifications of ,β  and n1 , to accomodate complex prevention schemes, such as selections 
of risk group sub-populations and communicable (infectious or hereditary) diseases. 
 
 
4.1 Variable Stage Survival 
 
Let us suppose that an affected individual has a life expectancy at disease onset time t given 
by 


t
dw
tS
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tE
)(
)(
)( . Since, in general, the exact time of onset of the disease is unknown, the 
disease staging may be effectively used to approximate the survival experience as a discrete 
function of the severity rather than the time elapsed: iS , ni 1 . Thus the corresponding 
life expectancies 
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n
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 generate a new set of costs, where original average stage costs 
i , ni 1  are associated to life expectancy at each detection stage: ji E , njiji 1, ;   
and (12) turns into  
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where E  
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4.2 Communicable diseases 
 
The extension of the model to communicable diseases prevention must account for all 
secondary cases that an unscreened individual may potentially generate during his whole 
infectious life. Not very different is the case of hereditary syndroms and affections of all sorts.  
Similarly to the previous section, the vector n1  turns into   niin s ,,11  s1 , where the is , 
ni 1  are the average numbers of secondary cases generated by an infective individual in 
stage i, .1 ni   Therefore (12) becomes  
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and, still similarly to the previous case, new stage costs are generated as  ji s1 , 
.1, ; njiji   
 
 
5. Final Remarks and Further Developments 
 
The model here presented is based on health care hypotheses that apply to most public health 
schemes. Moreover, current ethical and social issues have no part in the approach here 
presented. The model is flexible enough to be further extended as to include more complex 
issues as shown in section 4. It is, however, interesting to notice that the matrix form 
expressions (12) allow for a geometrical interpretation of the prevention structure: in fact, the 
bilinear forms in (12) are degenerate (the matrices B1 and B2 are singular), thus mapping the 
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unit n-vector (representing a non-informative individual) onto the (n-1)-space of treatment 
unit costs, where the reduction of dimensions is due to the fact that only non-zero cost 
differences are considered. This amounts to representing an unsorted (non-informative), 
affected individual in terms of cost reduction if positively sorted by some forms of 
prevention/screening for the disease under study. As shown in section 4, any further 
improvement to this model can, therefore, be attained by new geometrical definitions of the 
space of individuals, of the space of treatment costs or a combination of both, so as to 
possibly include targeted prevention measures and/or selective treatment costs. 
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